Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Interest & Investment Income (2022 - 2026)

TriSalus Life Sciences has reported Interest & Investment Income over the past 5 years, most recently at $164000.0 for Q1 2026.

  • For Q1 2026, Interest & Investment Income rose 121.62% year-over-year to $164000.0; the TTM value through Mar 2026 reached $645000.0, up 67.1%, while the annual FY2025 figure was $555000.0, 37.38% up from the prior year.
  • Interest & Investment Income for Q1 2026 was $164000.0 at TriSalus Life Sciences, down from $177000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $314714.0 in Q2 2022 and troughed at $35000.0 in Q1 2023.
  • A 5-year average of $122347.9 and a median of $105000.0 in 2022 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: plummeted 88.56% in 2023 and later skyrocketed 210.53% in 2025.
  • Year by year, Interest & Investment Income stood at $105000.0 in 2022, then skyrocketed by 132.38% to $244000.0 in 2023, then plummeted by 76.64% to $57000.0 in 2024, then skyrocketed by 210.53% to $177000.0 in 2025, then fell by 7.34% to $164000.0 in 2026.
  • Business Quant data shows Interest & Investment Income for TLSI at $164000.0 in Q1 2026, $177000.0 in Q4 2025, and $170000.0 in Q3 2025.